Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment

1 Mar 2018

Abstract excerpt

Abstract: Tacrolimus is a commonly used immunosuppressant after kidney transplantation. It has a narrow therapeutic range and demonstrates wide interindividual variability in pharmacokinetics, leading to potential underimmunosuppression or toxicity. Genetic polymorphism in CYP3A5 enzyme expression contributes to differences in tacrolimus bioavailability between individuals. Individuals carrying one or more copies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pharmacogenetics and Drug Metabolism
Share to Pharmacological Effects and Toxicity Studies
Share to Renal Transplantation Outcomes and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29563827
DOI: 10.2147/pgpm.s107710

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatmentPMID 29563827Read ↗

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.Semantic proximity Read ↗

A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

Impact of CYP3A5 Gene Polymorphisms on Tacrolimus Pharmacokinetics and Renal Allograft Rejection in Kidney Transplant Recipients: A Meta-Analysis Across Ethnic PopulationsSemantic proximity Read ↗

Genotype-guided tacrolimus dosing: The role of CYP3A5 polymorphisms in optimising kidney transplant immunosuppression in BhutanSemantic proximity Read ↗

Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.Semantic proximity Read ↗

Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients.Semantic proximity Read ↗

CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression.Semantic proximity Read ↗

Renal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients-Preliminary Report.Semantic proximity Read ↗

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Semantic proximity Read ↗

Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.Semantic proximity Read ↗

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.Semantic proximity Read ↗

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.